Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK chain pulls analgesic promotion

This article was originally published in The Tan Sheet

Executive Summary

Tesco for the second time withdraws a volume-based promotional offer for analgesics after a competitor, Alliance Boots, complains the promotion violates restrictions on retail pack sizes, the Medicines & Healthcare products Regulatory Agency (MHRA) announces Oct. 4. Tesco offered a "two for one" promotion for Wrafton Laboratories' Resolve and Resolve Extra acetaminophen products, according to the MHRA release. However, Alliance Boots told MRHA the promotion exceeds the guideline on restricting consumers' purchases of analgesics that UK retailers have agreed to follow. The British retailer withdrew a similar promotion in June 2005 (1The Tan Sheet" June 27, 2005, In Brief). The health authority reached agreements with several other retailers, according to the release...

You may also be interested in...



MHRA analgesic marketing

Volume-based painkiller promotions have been withdrawn by British retailers Tesco and Superdrug following two complaints upheld by the Medicines & Healthcare products Regulatory Agency, the health agency announces June 14. MHRA notes promotional offers such as "two for the price of one" and "buy one, get one free" undermine the government's limits on analgesic pack sizes, referencing a 2004 British Medical Journal study which linked reductions in suicides and liver toxicity to size restrictions (1"The Tan Sheet" Nov. 8, 2004, p. 9). The government "will consider changing the law if retailers do not act responsibly," MHRA Policy Group Manager Jeremy Mean notes...

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says

Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel